Onco360 ®, the nation’s leading independent specialty pharmacy, has been selected as a national pharmacy partner by Astellas for Vyloy ® (zolbetuximab-clzb), approved in combination with ...

Thanks to the recently published data, zolbetuximab has now been approved as a drug in Europe. Patients with gastric cancer are expected to be able to be treated with it in Germany from the end of ...

Thanks to the recently published data, zolbetuximab has now been approved as a drug in Europe. Patients with gastric cancer are expected to be able to be treated with it in Germany from the end of ...

VYLOY is the first and only CLDN18.2-targeted treatment approved in the U.S. for adults with advanced gastric and gastroesophageal junction cancer whose tumors are CLDN18.2 positive In the ...

Investigational Pipeline in CLDN18.2 A Phase 2 trial of zolbetuximab in metastatic pancreatic adenocarcinoma is in progress. The trial is a randomized, multi-center, open-label study, evaluating ...

They show that patients with advanced gastric cancer treated with zolbetuximab live longer. The progression of the disease is delayed. This is an important step forward for patients suffering from ...

Investigational Pipeline in CLDN18.2 A Phase 2 trial of zolbetuximab in metastatic pancreatic adenocarcinoma is in progress. The trial is a randomized, multi-center, open-label study, evaluating the ...